News | August 11, 2014

Elekta Leksell Gamma Knife Perfexion Earns Top Rank in 2014 Best in KLAS for Radiation Therapy

Elekta Leksell Gamma Knife Perfexion 2014 Best in KLAS Radiation Therapy

August 11, 2014 — Elekta’s Leksell Gamma Knife Perfexion radiosurgery system took the first place ranking for the fourth consecutive year in KLAS research firm’s recently released 2014 Best in KLAS Awards: Medical & Infrastructure report. In addition, Elekta’s Agility 160-leaf multi-leaf collimator (MLC) and Elekta Infinity radiation treatment system earned second and third place.

In the report, Perfexion scored 94.5 out of 100 on the system’s functionality and upgrade capacity. Perfexion also scored between 90.5 and 93.5 on four other performance categories, including service and support, and implementation and training.

Further documenting the superior dosimetric performance of Perfexion, a recent multicenter study [1] showed that the system offers dramatically lower radiation dose to normal brain — in the treatment of multiple metastases — than other systems, such as Varian’s TrueBeam flattening filter-free linear accelerator with a 2.5 mm MLC. Patients with multiple metastases, the report said, stand to receive as much as a 74 percent lower radiation dose to normal brain tissues if the lesions are treated with Perfexion versus contemporary linear accelerator-based stereotactic (SRS) systems.

KLAS surveys include opinions of thousands of health care professionals The KLAS awards are based on data from customer surveys of hospital and clinic executives, administrators, physicians, nurses and other directors and managers interacting with health care equipment and infrastructure solutions.

According to KLAS, Best in KLAS designations go to solutions that have excelled in their respective market segments, that show the vendor’s leadership in working with customers to resolve issues and match expectations to reality, and that have the broadest operational and clinical impact to health care organizations.

The Best in KLAS designation recognizes vendors for their outstanding efforts to help healthcare professionals deliver better patient care. This award is reserved for those that lead the imaging equipment segments with the broadest operational and clinical impact on healthcare organizations.

“This is a tremendous achievement because each of the top performers earned this recognition through the voice of their provider customers,” says Matt Terry, vice president of medical equipment and imaging research for KLAS. “Given that vendors must concern themselves with the complexities of a dynamic health care market and operational challenges, it is remarkable to see so many undeviating from their focus on helping providers succeed.”

For more information: www.KLASresearch.com, www.elekta.com

References:

1.Ma L, Nichol A, Hossain S, et al. (2014) Variable dose interplay effects across radiosurgical apparatus in treating multiple brain metastases. Int J CARS. Published online: 20 April 2014. doi:10.1007/s11548-014-1001-4

Related Content

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017
Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC) covering North Carolina,...
Overlay Init